UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OF 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
November 4, 1999 (Date of earliest event reported)
GUM TECH INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)
UTAH 0-27646 87-0482806
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
246 East Watkins Street, Phoenix, Arizona 85004
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (602)252-1617
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS.
Attached hereto as Exhibit 99.1 is a copy of Gum Tech International, Inc.'s
press release dated November 4, 1999 titled "Gum Tech Announces Withdrawal of
Journal Article."
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Gum Tech International, Inc. Press Release November 4, 1999
titled "Gum Tech Announces Withdrawal of Journal Article"
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GUM TECH INTERNATIONAL, INC.
(Registrant)
By /s/ William J. Hemelt
-----------------------------------
(Signature)
William J. Hemelt
Secretary and Chief Financial Officer
Date: November 8, 1999
2
<PAGE>
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Gum Tech International, Inc. Press Release November 4, 1999
titled "Gum Tech Announces Withdrawal of Journal Article"
3
COMPANY PRESS RELEASE
Gum Tech Announces Withdrawal of Journal Article
WOODLAND HILLS, Calif., Nov. 4 /PRNewswire/ -- Gel Tech, a joint venture of Gum
Tech, International (Nasdaq: GUMM - news) and Bio Delivery Technologies,
announced today that the American Journal of Infection Control (AJIC) is
withdrawing the manuscript "The effect of direct application of ionic zinc nasal
spray gel on the duration of the common cold" from publication. The Journal had
planned on using the study in a future issue.
According to Elaine Larson, editor of AJIC, the peer review process was in order
and the manuscript was reviewed by experts in the field. It followed an accepted
blind review process. However, based on the pre-release of data and related
issues not in compliance with the established policies and copyright regulations
of the Journal, the manuscript has been withdrawn from publication.
"This in no way reflects on the positive results or the integrity of the study,"
said Dr. Charles Hensley, scientific affairs director at Gel Tech. The initial
internal study found that Zicam significantly reduced the duration of the common
cold.
Hensley said, "We are continuing our research on Zicam with a separate
large-scale independent clinical study. We expect the results of that study to
be announced in the near future and submitted for publication at a later date in
compliance with all required protocols."
Gum Tech Forward-Looking Statement:
This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements regarding
the positive results of the Company's internal clinical study on Zicam, the
ability of Zicam to reduce the duration of the common cold, and the expected
time that any separate independent clinical results will be announced and
whether or not those results will be submitted for publication. These
forward-looking statements are based on the Company's expectations and are
subject to a number of risks and uncertainties, many of which cannot be
predicted or quantified and are beyond the Company's control. Future events and
actual results could differ materially from those set forth in, contemplated by,
or underlying the forward-looking statements. Factors that could cause actual
results to differ materially from the Company's expectations include the
possibility that pending clinical trials will produce less favorable than
anticipated results regarding the efficacy of Zicam, the possibility that users
of Zicam may not realize the results suggested by the internal clinical study,
the possibility that the outcome of any large-scale independent clinical study
may be less positive than the results suggested by the initial internal clinical
study, and the possibility that any studies submitted by the Company for
publication may not be accepted or may be rejected. Other factors that could
cause actual results to differ materially from the Company's expectations are
described in the Company's reports filed pursuant to the Securities Exchange Act
of 1934.
